Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue?

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 4, 2025

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 3, 2025

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 3, 2025

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. ( RARE ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Founder, President, CEO & Director Erik Harris - Executive VP & Chief Commercial Officer Howard Horn - Executive VP of Corporate Strategy & CFO Eric Crombez - Chief Medical Officer & Executive VP Conference Call Participants Huidong Wang - Barclays Bank PLC, Research Division Maurice Raycroft - Jefferies LLC, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Maxwell Skor - Morgan Stanley, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Will Soghikian - Leerink Partners LLC, Research Division Joyce Chang Robbins - JPMorgan Chase & Co, Research Division Steve Scala - TD Cowen, Research Division Mehdi Goudarzi - Truist Securities, Inc., Research Division Mitchell Kapoor - H.C.

Seeking Alpha • Nov 5, 2025

Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y

RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.

Zacks Investment Research • Nov 5, 2025

Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates

Ultragenyx (RARE) came out with a quarterly loss of $1.81 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to a loss of $1.4 per share a year ago.

Zacks Investment Research • Nov 4, 2025

Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 Earnings

The headline numbers for Ultragenyx (RARE) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Nov 4, 2025

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55 times the purchase price Proceeds to fund four expected launches, setting the company up for the next stage of growth NOVATO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced the sale, for $400 million, of an additional 25% of the company's royalty interest from Kyowa Kirin Co., Ltd on the future sales of Crysvita® (burosumab) in the United States (U.S.) and Canada to OMERS, one of Canada's largest defined benefit pension plans.

GlobeNewsWire • Nov 4, 2025

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, November 4, 2025, to discuss its financial results and corporate update for the quarter ending September 30, 2025.

GlobeNewsWire • Oct 28, 2025

Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 28, 2025